Abstract
U.S. drugmaker Merck & Co. and German diagnostics firm Qiagen are separately planning major investments in the U.K. The moves accompany a raft of British government measures intended to bolster the life sciences sector as the country prepares to leave the European Union. Merck is set to invest $1.3 billion to build a new U.K. headquarters and drug research center in the London area. Scheduled to open in about 2020, the facility will house 150 new researchers plus 800 staffers currently working in Hoddesdon, north of London. “This new London location will enable us to … be an important contributor to the vibrant and rapidly growing London life sciences community, while providing access for more collaborations within the European life science ecosystem,” says Roger M. Perlmutter, president of Merck Research Laboratories. In the near term, Merck plans to establish a small temporary research facility in the London area. The firm
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
